Skip to main content
Delfa

← All assets

Buntanetap

5 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

5

Ongoing

1

Recruiting

0

Completed

3

Sites

138

Countries

1

Endpoints

53

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 53 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 1
1
Phase 1/2
2
Phase 2/3
1
Phase 3
1

Trials by status

Active, not recruiting
1
Completed
3
Terminated
1

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Global cognition
14
Fluid / digital biomarkers
9
Other (unclassified)
8
Safety / tolerability / PK
7
Amyloid biomarkers
5
Function / daily living
3
Behavior / neuropsychiatric
2
Neurodegeneration biomarkers
2
Other clinical outcomes
2
Tau biomarkers
1

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 19 of 53 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

ADAS-CogCognition

8

Mini-Mental State Examination (MMSE)Cognition

4

ADCS-Activities of Daily Living (ADCS-ADL)Function

3

Neurofilament light (NfL)Neurodeg.

2

Neuropsychiatric Inventory (NPI)Behavior

2

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

5 of 5

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
NCT06709014A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

Buntanetap

Alzheimer’s disease

Alzheimer's diseasePh 3Active, not recruiting78Dec 2027-
NCT05686044A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD

Buntanetap

Alzheimer’s disease

Alzheimer's diseasePh 2/3Completed54Feb 2024-results
NCT04524351Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients

Buntanetap

Alzheimer’s disease

MMSE 18-28Ph 1/2Completed13Aug 20211results
DISCOVERSafety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease

Buntanetap

Alzheimer’s disease

CDR global 0.5Ph 1/2Completed6Dec 20212results
NCT01072812Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment

Buntanetap

Alzheimer’s disease, MCI / preclinical Alzheimer’s

MMSE ≥24Ph 1Terminated1Jul 2010-

Showing 1-5 of 5 trials